November 30, 2020 07:00 AM EST

Scoop: Google’s GV spearheads the Spotlight syndicate — backing an upstart biotech aimed at ‘democratizing’ gene editing

John Carroll

Editor & Founder

CRISPR had no sooner started to shake the very foundations of drug development before its limitations began to loom large. Gene editing could change the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: Google’s GV spearheads the Spotlight syndicate — backing an upstart biotech aimed at ‘democratizing’ gene editing

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Scoop: Google’s GV spear­heads the Spot­light syn­di­cate — back­ing an up­start biotech aimed at ‘de­moc­ra­tiz­ing’ gene edit­ing

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Scoop: Google’s GV spearheads the Spotlight syndicate — backing an upstart biotech aimed at ‘democratizing’ gene editing

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.